Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
The current treatment armamentarium for non-small-cell lung cancer (NSCLC) is dominated by biomarker-driven therapies and immune checkpoint inhibitors. Therapeutic options in this indication have…
Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…
Clarivate Epidemiology's coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key non-small-cell lung cancer patient populations covering 171 countries…
Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of NSCLC comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NSCLC for each…
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…